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Summary.-Eighty-two per cent of tumour sections from 105 patients with lung can-
cer showed positive immunocytochemical localization of an anti-carcinoembryonic
antigen (CEA) immunoglobulin free of antibody to normal cross-reacting antigen
(NCA). The highest incidence was found in adenocarcinomas, and no association
between staining and disease stage was found. There was a relationship between
positive-staining tumours and preoperative and postoperative serum CEA levels
of >,20 ng/ml, but the high incidence of CEA+, <20 ng/ml serum patients indicated
that immunocytochemical localization was of little value in selecting patients for
sequential serum monitoring. Staining for CEA was not prognostic but a preopera-
tive serum CEA level 3z20 ng/ml was associated with a poor prognosis in patients
undergoing radical surgery for lung cancer (P=0-043). This prognostic effect of CEA
was seen mainly in patients whose tumours showed the greatest immunocyto-
chemical localization (P=0 017) and in Stage III patients (P=0.04).
SINCE its original description (Gold &
Freedman, 1965) carcinoembryonic anti-
gen (CEA) has been identified in a variety
of benign and malignant diseases, includ-
ing lung cancer. It has been found in the
serum (Lo Gerfo et al., 1971; Laurence
et al., 1.972; Vincent & Chu, 1973; Newman
et al., 1976) and shown by immunocyto-
chemical techniques to be present in lung
cancer tissue (Pascal et al., 1977; Golden-
berg etal., 1978; Hill etal., 1979). However,
in the management of patients with lung
cancer there is still disagreement as to its
value as a prognostic indicator or as a
reliable monitor ofrecurrence and response
to treatment (Ford et al., 1979; GCropp
et al., 1979). In part, this may be due to
differences in reagents and in sensitivities
of the assays used in the various studies.
This is particularly true of the in vitro
localization investigations, where tech-
niques such as immunodiffusion and
immunoelectrophoresis are often used to
assess the specificity of anti-CEA sera by
* To wbom correspolldellce sboul(l be addressed.
excluding the presence ofantibodies to the
CEA-cross-reacting normal cross-reacting
antigen (NCA). After showing specificity
by these methods, antisera are then used
in more sensitive immunocytochemical
tests to determine the expression of CEA
and the possibility of cross-reacting anti-
bodies being detected in these tests is not
considered further.
The objectives ofthis investigation were
to use an anti-NCA-free anti-CEA anti-
body in an indirect immunoperoxidase
test to determine the expression of CEA
in lung-cancer tissue sections; to examine
whether there was a correlation between
the presence of CEA staining and serum
levels of the antigen, and whether tissue
staining could predict those patients in
whom sequential monitoring might be of
value; and finally, to investigate whether
the presence of CEA in the tumour or
in the serum was ofprognostic significance
in patients undergoing radical surgery for
lung cancer.C. H. J. FORD, H. J. STOKES AND C. E. NEWMAN
MATERIALS AND METHODS
Patients and tissue specimens.-Operative
specimens were obtained from 105 patients
who underwent radical surgery for lung
cancer, and who were entered into a controlled
trial of passive immunochemotherapy (New-
man et al., 1977). After fixation in 10%
buffered formalin, specimens were embedded
in paraffin wax and routinely processed to
provide 5-7,um sections for histology. For
103 patients, primary tumour tissue was
available. For 2 patients, only tumour tissue
from involved lymph nodes, removed at
surgery, was available. The lung cancers
were histologically proven adenocarcinomas
(adeno), poorly differentiated squamous-cell
carcinomas (PDSCC), non-small-cell anaplas-
tic carcinomas (anaplastic) and small-cell
anaplastic (SCA) carcinomas. The Working
Party for the therapy of lung cancer (WP-L)
classification was used (Mathews, 1973).
Well differentiated squamous-cell carcinomas
were not available for study, as patients with
this type of lung cancer were not eligible for
the clinical trial because of their better prog-
nosis than other histological types. Patients
were staged using clinico-pathological criteria
(Mountain, 1976). Serum samples were ob-
tained where possible preoperatively;monthly
after surgery for 3 months; then at 3-monthly
intervals for 3 years and thereafter at 6-
monthly intervals.
Antisera.-A sheep anti-CEA immuno-
globulin (Ig), supplied by Dr A. R. Bradwell,
Immunodiagnostics Research Laboratory,
University of Birmingham, was used in this
study. Details of the preparation of this
antibody and its in vivo use have been repor-
ted elsewhere (Dykes et al., 1980). Before
fractionation, the antiserum had been ab-
sorbed once with glutaraldehyde-polymerized
human serum and 3 times with glutaralde-
hyde-fixed normal tissue from colon, spleen,
lung and liver, until it gave a single line on
immunoelectrophoresis. After ammonium
sulphate fractionation and DE52 chromato-
graphy, this Ig still cross-reacted with NCA,
as determined by immunoperoxidase staining
of NCA-containing myeloid cells in sections
of normal human spleen, and leukaemic cells
from patients with chronic myeloid leukaemia
(CML). The Ig was absorbed with polymerized
spleen until it was negative with spleen and
CML cells with which it had previouslv been
positive in the immunoperoxidase test (a
further 3 absorptions). This Ig showed charac-
teristic luminal localization on sections from
CEA-secreting colonic carcinomas,andstained
liver metastases from colon-cancer primaries.
It was then used in these experiments.
For a negative control in the immuno-
peroxidase test, anti-CEA activity was re-
moved from an aliquot of this Ig by absorp-
tion with CEA prepared and purified in this
laboratory by Mr J. A. Griffin and Mr C. S.
Woodhouse, using the method of Pritchard &
Egan (1978) without the final ConA-affinity
purification. An immunosorbent column was
prepared by coupling 2-5 mg of CEA to AH
Sepharose, using the method of Burtin &
Gendron (1978). The CEA used for coupling
was from a different source from that used
for raising the anti-CEA serum. After absorp-
tion, the anti-NCA-free anti-CEA Ig no longer
stained sections from CEA-secreting colon
cancers, and was used as a control in the
immunoperoxidase test. A rabbit anti-sheep
IgG-horseradish peroxidase conjugate (Nor-
dic) was used as the second antibody in the
test.
Immunoperoxidase technique.-The two-
stage immunoperoxidase techniqueas detailed
by Heyderman (1979) was used. After block-
ing aldehyde groups with 0.02% sodium boro-
hydride, a step was introduced in which 100 ,l
of a 1/25 dilution of normal rabbit serum was
incubated with the sections for 10 min,
followed by washing with PBS. One hundred
,ul of a 1/50 dilution of anti-CEA Ig in 1%
BSA in PBS was then incubated with the
sections for 30 min. After the next washing
step, 100 ,ul of a 1/80 dilution of rabbit anti-
sheep IgG-peroxidase conjugate was incu-
bated for 30 min with the sections, and the
rest of the test procedure performed as des-
cribed by Heyderman (1979). Controls in4
cluded 2 sections from the same paraffin
block treated with a 1/50 dilution ofthe CEA
absorbed anti-CEA or a 1/100 dilution of 1%
BSA instead of the anti-CEA Ig. The rest of
the technique was identical.
The incubation with normal rabbit serum
was found to be an essential step. In initial
experiments this was omitted, and it was
found necessary to absorb the rabbit anti-
sheep conjugate with glutaraldehyde-poly-
merized human tissue to reduce the back-
ground non-specific staining. However, when
the anti-NCA-free anti-CEA Ig was then
used, it would only stain lung tumours after
the sections had previously been treated with
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0.1% trypsin, resulting in a loss of CEA
specificity (Ford et al., 1980a). This problem
was overcome by incubating with normal
rabbit serum after the step of blocking alde-
hyde groups. Absorption ofthe conjugate and
treatment of the sections with trypsin were
then no longer necessary.
Interpretation of staining.-The staining
reaction for CEA was interpreted with refer-
ence to the control sections with 1% BSA
and with the CEA-absorbed anti-CEA Ig.
Any staining in the test section which was
absent from the absorbed anti-CEA control
was scored as positive. No attempt was made
to grade the intensity of staining but the
amount of tumour tissue stained was qualita-
tively graded into 2 types:
Type 1.-> 70% of tumour cells stained, or
scattered clumps of tumour cells stained
with most of the cells in a clump staining.
Type 2.-scattered positive clumps oftumour
cells with few of the cells in a clump
stained; or only a few areas of tumour
stained; or only a few positive tumour cells
in the entire section.
Assessment was carried out independently by
2 observers, and there was over 90%
agreement between them. When there was
disparity the slides were reassessed. This
always led to agreement between the obser-
vers.
Serum CEA assay.-A modified double
radioimmunoassay performed in Dr Dyke's
Laboratory, Department of Immunology,
was used (Egan et al., 1972; Booth et al.,
1973). The upper limit of the normal range
with this assay is 15 ng/ml, and the use of
this test for measuring CEA in serum samples
from lung-cancer patients has been reported
previously (Ford et al., 1977).
Life-table analy.sis-.The logrank and life-
table method (Peto et al., 1977) was used to
assess the prognostic value of CEA in these
105 patients, with a minimum follow-up 212
years and a maximum of 5- years after sur-
gery. A DEC PDP 11/40 computer in the
Department of Medical Physics, Queen
Elizabeth Hospital, was used for the analysis,
and the help and advice ofDr Edwin Claridge
is gratefully acknowledged.
RESULTS
The incidence ofCEAstaininginsections
from the lung-cancer patients in this study
TABLE I.-% incidence of CEA staining
in lung-cancer tissue (number of cases in
parentheses)
Staining category
A~~~~~~~~~'
All cases
(105)
Adeno
(20)
PDSCC
(55)
Anaplastic
(22)
SCA
(8)
Negative
18-1
(19)
10
(2)
14-5
(8)
27
(6)
37-5
(3)
Positive
Total Type 1 Type 2
81-9 58-1 23-8
(86) (61) (25)
90 85 5
(18) (17) (1)
85-5 49-1 36-4
(47) (27) (20)
73 59 14
(16) (13) (3)
62-5 50 12-5
(5) (4) (1)
Adeno=Adenocarcinomas; PDSCC=poorly differ-
entiated squamous-cell carcinomas; Anaplastic =
non-small-cell anaplastic carcinomas; SCA =small-
cell anaplastic carcinomas.
is given in Table I. Eighty-two per cent
of sections were positive, 58% Type 1 and
24% Type 2. The incidence of CEA stain-
ing was greatest in adenocarcinomas
(90%) followed by PDSCC (85.5%), ana-
plastic (73%) and SCA (62.5%) carcino-
mas. The difference was more pronounced
when only Type 1 staining was considered.
Then 85% of adenocarcinomas were posi-
tive compared with 49-59% for the other
histological types. The relationship be-
tween staining and disease stage was also
investigated. There was little difference in
the total percentage of positives between
Stage I and Stage III patients, though
73% of Stage III patients exhibited Type
1 stainingandonly 52% ofStageIpatients.
Little can be said about the Stage II
patients, of whom there were only 8.
Comparison of immunocytochemical
anti-CEA localization with serum CEA
levels is shown in Table II for the 86
patients for whom there were both pre-
operative andpostoperative serumsamples
available for assay. The upper limit of
normal with this assay was 15 ng/ml.
Because patients with lung cancer are
often bronchitic and cigarette smokers,
and as both bronchitics and smokers often
have slightly higher serum CEA levels,
20 ng/ml was selected as a cut-off for the
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TABLE II.-Correlation between CEA-staining oflung tumour tissue and serum CEA level
(number of cases in parentheses)
Staining category
t
A
Serum
CEA
Samples (ng/ml) Negative
Preoperative < 20 24-6
(61) (15)
320 8
(25) (2)
20-49 12-5
(16) (2)
350 0
(9) (0)
Postoperative < 20 23-3
(30) (7)
320 18
(56) (10)
20-49 22-9
(35) (8)
350 9-5
(21) (2)
test. The results are therefore presented
in terms of a CEA level of < 20 ng/ml or
3 20 ng/ml, and the latter group are
sub-divided into 20-49 ng/nl and 3 50
ng/ml categories. In both the preoperative
and postoperative groups there was an
increase in the total percentage ofpositive
staining as the serum CEA level increased.
In 9 patients with preoperative CEA levels
of 3 50 ng/ml, all were positive and all had
Type 1 staining. In the post-operative
group, 90% of the 3 50 ng/ml patients
were positive but the concordance with
Type 1 staining was less (76%). Interest-
ingly, 8% (2) ofpatients with preoperative
and 18% (10) of patients with postopera-
tive levels of 3 20 ng/ml were negative for
CEA in the immunoperoxidase test, in-
cluding 2 patients who had postopera-
tive levels of 3 50 ng/ml. Seventy-five
per cent of patients with a preoperative
level of < 20 ng/ml and 77% ofthose with
levels of < 20 ng/ml postoperatively had
tumours which were CEA+.
Forty per cent of the patients in this
study are alive and recurrence free; half
of them have never had a preoperative
CEA level of 3 20 ng/ml and a third
have never had a postoperative level
3 20 ng/ml. We felt this might be the
explanation for the 75% and 77% of
Positive
Total
75-4
(46)
92
(23)
87-5
(14)
100
(9)
76-7
(23)
82
(46)
77-1
(27)
90 5
(19)
Type 1
47-5
(29)
76
(19)
62-5
(10)
100
(9)
53-3
(16)
57
(32)
45-7
(16)
76-2
(16)
Type 2
27-9
(17)
16
(4)
25
(4)
0
(0)
23-3
(7)
25
(14)
31-4
(11)
14-3
(3)
CEA+, <20ng/ml patients in the 2
groups. We therefore looked only at
patients who had recurred and died, and
for whom we had pre- and postoperative
serum samples using 20 ng/ml as the cut
off. This made no difference to the pre-
operative group but it did result in a small
reduction to 69% in the percentage of
CEA+, <20ng/ml patients in the post-
operative group.
In terms of prognosis, when looked at
by logrank and life-table analysis, there
was a slight non-significant difference
between patients with Type 2 staining and
patients with negative or Type 1 tumours
(Fig. la). When positive was compared
with negative, without subdivision, there
was no difference between the groups
(Fig. lb). The prognostic influence of a
preoperative CEA level < 20 ng/ml, 20-49
ng/ml or 3 50 ng/ml is shown in Fig. 2a.
It can be seen that the 20-49 ng/ml and
3 50 ng/ml groups have the same survival
characteristics, but that the < 20 ng/ml
group has a better prognosis. For this
reason we felt justified in combining 2
groups and comparing < 20 ng/ml with
3 20 ng/ml (Fig. 2b) and a significant
difference in prognosis was found, with
patients in the < 20ng/ml group having a
projected survival rate of 50% compared
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FIG. 1. Effect of CEA+ staining on survival
after radical surgery. (a) Positives sub-
divided into Type 1 ( , 61) and Type 2
(- , 25) staining; CEA-, ----, 19. (b) All
CEA+ ( , 86) Vs CEA (----, 19). All
differences non-significant.
with 15% for patients with levels 3 20
ng/ml (P = 0 043). When the combined
pre- and/or postoperative group was
analysed in the same way, no difference
in survival was seen between the cate-
gories.
The prognostic influence of a preopera-
tive CEA level above or below 20 ng/ml
was looked at in relation to some of the
factors which might influence the produc-
tion of CEA: whether tumours showed
localization of anti-CEA Jg; histological
399 798 1198
DAYS FROM SURGERY
1597 1996
FIG. 2. Effect of preoperative CEA serum
level on survival after radical surgery.
(a) Analysed for 3 levels, P=0-123;
, <20 ng/ml (61); ----, 20-49 ng/ml
(16); , 650 ng/ml (9). (b) Analysed
for 2 levels, P=0-043; - as in (a);
3 20 ng/ml (25).
type and disease stage. Only 2 patients
with tumours which were negative for
CEA staining had 3 20 ng/ml preopera-
tively. Patients with tumours showing
localization of anti-CEA antibodies and
3;20 ng/ml preoperatively, had a worse
prognosis than patients with positive
staining and < 20 ng/ml, though this did
not reach statistical significance. How-
ever, when patients with Type 1 staining
with preoperative CEA levels of < 20 or
3 20 ng/ml were compared there was a
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FIG. 3. Survival and preoperati3
serum level for: (a) Type E
P=0-017; (b) Stage III disease;,
In each figure, = < 20 ng/m]
b, 20); ----=320 ng/ml (a, 19; b,
significant difference in pro
favour of those with the lob
(P=0-017, Fig. 3a). There wei
patients (4) with 3 20 ng/ml iD
2 category to make a similar c
Looked at in relation to histo
were only small numbers of I
the 3 20ng/ml group for any
histological type. However, i
with PDSCC tumours, no diffi
seen; in the anaplastic group
SCA and non-SCA) the 3 20ng/i
had a worse survival than pal
< 20 ng/ml (non-significant) ai
the adenocarcinoma group did this differ-
ence approach significance (P= 0.08). With
regard to Stage, there was no difference in
survival between Stage I patients with
< 20 or 3 20 ng/ml. The prognostic sig-
nificance of preoperative CEA was only
seen in Stage III patients where patients
with 3 20 ng/ml had a worse survival
(P =0*04, Fig. 3b). There were insufficient
Stage II patients for analysis.
DISCUSSION
In this investigation, 82% of sections
1597 1996 from patients with lung cancer stained
positively for CEA. Ifonly the histological
types investigated in this study are con-
b sidered, this overall figure is much greater
than the 50% obtained by Pascal et al.
(1977) and the 25% obtained by Golden-
berg et al. (1978) in patients with adeno-
and squamous-cell carcinomas ofthe lung.
However, it is similar to the overall figure
of 81.5% obtained from the data of Hill
et al. (1979) with similar histological types.
Ninety per cent of adenocarcinomas were
positive and this agrees with the 87.5%
quoted by Hill et al. (1979). Goldenberg
et al. (1978) obtained a much lower figure
of 31% in their study. For PDSCCs our
159i 1996 figure of 85.5% is also higher than that
reported by others for all squamous-cell
e CEA carcinomas; 22% (Pascal et al., 1977) and
Staining; 24% (Goldenberg et al., 1978) and 69%
P-=0-04. (a, 29; (but only 1/5 PDSCCs were positive; Hill
11). et al., 1979). Hill et al. (1979) also reported
3/3 SCA patients positive (our results
gnosis, in 5/8).
ver values The high incidence of positive staining
re too few obtained in this study was surprising.
i the Type However, we are confident that this does
Dmparison. reflect the CEA distribution, uncompli-
,logy, there cated by NCA detection, in view of the
)atients in particular care that was taken in estab-
particular lishing the anti-CEA specificity of the
n patients Ig and in excluding antibodies to NCA
erence was detectable in the immunocytochemical
(combined test. The high percentage of adeno-
rnl patients carcinomas which showed anti-CEA local-
ients with ization agrees with our experience with
nd only in serum CEA levels, where we have found
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that 26% (7/27) of adenocarcinomas of
the lung had very high ( 3 50 ng/ml) pre-
operative levels, a much higher percentage
than any of the other histological types
(Ford et al., 1977). Initially, others were
unable to detect such an association with
the histological type of lung cancer
(Laurence et al., 1972) but more recently
this has been confirmed (McKenzie et al.,
1977; Vincent et al., 1979).
We found no difference in overall posi-
tive frequency between patients with
Stage I and Stage III disease, though there
was a higher incidence of Type 1 staining
in Stage III patients. Extent of disease
(as defined by stage) was, therefore, not
reflected by immunocytochemical posi-
tivity for CEA in our patients. An interest-
ing finding was that, although there was a
good correlation between a preoperative
CEA level of 3 20 ng/ml and immuno-
cytochemical localization (92%), 75% of
patients with levels lower than the cut-off
were also CEA+ in the immunoperoxidase
test. A similar result was obtained in the
postoperative group as well as in the
combined pre- and/or postoperative group.
Taking the higher cut-offof 3 50 ng/ml the
correlation with total staining and Type 1
staining was I00%/ in the preoperative
group but lower in the other 2 groups.
Even when these data were "corrected"
for the fact that many patients were alive
without recurrence, and only patients who
had recurred and died were analysed,
there were still over 6900 positively
stained tumours in patients with CEA
levels of < 20 ng/ml either preoperatively
or postoperatively.
One of the aims of this study was to
investigate whether there was a correlation
between immunocytochemical staining for
CEA and preoperative and postoperative
serum levels of the antigen, so that we
could determine whether tissue staining
might be valuable in predicting those
patients in whom sequential serum moni-
toring might be of benefit. In this study
over 82% (88% in the "corrected" group)
ofpatients who had 3 20 ng/ml either pre-
operatively or postoperatively, did stain
11
for CEA, but a sizeable percentage (over
7500, or 69% in the "corrected" group)
with <20 ng/ml also had positively
stained tumours. It would appear, there-
fore, that knowledge of the immunocyto-
chemical localization of anti-CEA anti-
bodies would be ofno value to the clinician
in selecting patients for sequential moni-
toring. A possible explanation for this
may be that the 20 ng/ml cut-off is not
the appropriate threshold. We feel, how-
ever, that the cut-off we have chosen is
valid, because it is higher than the upper
limit of the normal range in the radio-
immunoassay (15 ng/ml) thereby excluding
patients with small transitory rises above
the limit, and inparticularbecausepatients
with levels 20-49 ng/ml and 3 50 ng/ml
preoperatively have a similar prognosis
(Fig. 2a).
A criticism of immunocytochemical
investigations is that with a 5-7,um
section one is looking at a very small,
selected area of the tumour. This is more
of a problem when staining cannot be
demonstrated, and it might be argued that
the CEA-secreting area was missed when
the sections were cut. That was not a
problem in this study because of the high
incidence of positive staining. However, it
is conceivable that had we been able to
look at a large number of sections from
each tumour we might have found sections
in which some of the Type 2 staining
tumours were negative and the negative
tumours were positive. This is one of the
reasons why the positives were analysed
in 2 groups. We did not feel justified
in combining the Type 2 and negative
groups, as within the strict definition of a
positive as any staining of a tumour more
than in a CEA-absorbed control, Type 2
tumours were definitely CEA+. There was
no association of staining with prognosis,
irrespective ofthe type ofstaining, and the
19 patients with CEA- tumours had an
identical survival curve to that ofpatients
with CEA+ tumours (Fig. la, & b).
However, a preoperative serum CEA level
of 3 20 ng/ml was associated with a bad
prognosis. Although the cut-off level and
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method of assay differ, these results are
similar to those reported for adeno- and
squamous carcinomas of the lung (Con-
cannon et al., 1978) where all patients with
> 6 ng/ml died and survivors were only
foundinthe < 6ng/mlgroup. However, the
patients studiedbyConcannonwere allwho
had a thoracotomy and not just those who
received radical surgery, as in this study.
Dent et al. (1978) found no prognostic
effect of preoperative CEA level in 20
patients with resected lung cancers, but
patients with a CEA value of > 5 ng/ml
3 months after surgery had a significantly
worse prognosis than those with < 5ng/ml.
However, in a much larger series of 118
patients with surgical resection, Vincent
et al. (1979) found a significantly worse
prognosis for patients with a preoperative
CEA level > 2-5 ng/ml. Although the cut-
off level is different due to different assay
sensitivities, this parallels our experience,
and the 2 studies are similar in terms of
the numbers ofpatients studied and in the
surgical treatment. A similar result was
obtained by Stokes et al. (1980) in 43
patientsfollowedfor 2 years after complete
resection of a primary lung cancer, when a
preoperative level of < 21 ,ug/l was asso-
ciated with a significantly better prognosis
than 3 21 ,ug/l.
When looked at in relation to other
factors which might influence the produc-
tion of CEA, the prognostic effect of a
preoperative CEA level of 3 20 ng/ml was
only seen in tumours with the greatest
amount (Type 1) of anti-CEA staining
(P=0*017, Fig. 3a) and in patients with
Stage III disease (P = 0-04, Fig. 3b).
In this study, we have demonstrated
that the preoperative CEA level is a
prognostic indicator in patients who
undergo radical surgery, and thatimmuno-
cytochemical localization of anti-CEA Ig
on sections from lung cancers does not
enable us to reliably predict those patients
for whom postoperative CEA monitoring
might be of value. Although the antigenic
nature of lung cancers is being actively
investigated by a number of groups, in-
cluding our own (Ford et al., 1980b) and
potential tumour-associated markers have
been identified, CEA remains the best-
characterized tumour-associated marker in
lung cancer at present. The high per-
centage of lung tumours secreting CEA,
as detected immunocytochemically, is
encouraging in terms of the potential use
of anti-CEA antibodies for radioimmuno-
detection (Goldenberg et al., 1979; Dykes
et al., 1980) and may have important
clinical applications in terms of targeted
therapy in the future.
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